Atsena Therapeutics

Apnimed’s AD109 has the potential to be the first oral pharmaceutical drug that remedies both, the primary cause of OSA, nocturnal airway obstruction, and the daytime symptoms of OSA, such as fatigue. The dual mode of action of AD109 leads to upper airway dilatation as well as enhanced breathing and oxygen...

Mitochondria destruction can help in Cancer Treatment  Human cells require structures known as mitochondria for the generation of energy for their biochemical activities. Researchers at the Karolinska Institutet in Sweden thought that destroying these could be a strategy for cancer treatment.  Follo...